All posts by imreal

A Proactive Data Standards Strategy to Maximize Biopharma R&D Assets, Upcoming Webinar Hosted by Xtalks and Sponsored by Algorics


There is no one size fits all solution, but there is a solution for everyone.

In the past two decades, regulators have placed increasing emphasis on submitting standardized data. In an age where investments in clinical development continue to climb, it is important to understand how an effective data standards strategy can help biopharma companies improve efficiencies, to maximize returns on the R&D investment.

The adoption of data standards for small to mid-sized biotech companies is lower due to much smaller and product-focused portfolios, where investing in implementing, building and maintaining libraries can be a costly affair. Although, the absence of data standardization typically impacts companies at the end of the development journey, when clinical data has been handled by various CRO and technology partners, thus making managing, cleaning and analysis during submission stressful and resource intensive.

There is no one size fits all solution, but there is a solution for everyone. The key to success lies in aligning to long-term goals and implementing standardization in phases.

Register for this webinar to learn how a proactive data standards strategy can be crafted and effectively implemented, thus ensuring submission readiness while optimizing resources. Once standards are implemented, the options for automation are almost limitless, thus building efficiency and quality into processes.

Join Jason Housely, Head, Global Clinical Data Standards and Automation, Novartis; and Nithiya Ananthakrishnan, Founder and CEO, Algorics Inc., for the live webinar on Thursday, October 6, 2022, at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit A Proactive Data Standards Strategy to Maximize Biopharma R&D Assets.

ABOUT ALGORICS

Founded in 2013, Algorics is a specialized data sciences partner to the life sciences industry focusing on data management, biostatistics, programming, and data standardization. The company supports a global portfolio of biopharmaceutical and CRO clients with cost-effective and high-quality analytical services underpinned by technology know-how and access to high-quality talent across US, Europe and Asia. We help our customers increase productivity and accelerate development with our technology-backed solutions to enable data standardization and faster statistical reporting.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Vetster Named “Pet App of the Year” In 2022 Pet Independent Innovation Awards Program


News Image

Vetster is leading the global veterinary telehealth movement and revolutionizing the global pet care industry by bringing telehealth mainstream – Travis Grant, Managing Director, Independent Innovation Award

The 2022 Pet Independent Innovation Awards, an independent recognition platform highlighting the most innovative companies, services, and products in the highly competitive Pet care industry, today announced Vetster Inc., a leading veterinary telemedicine and pet-care marketplace, has been selected as “Pet App of the Year”.

Vetster is leading the global veterinary telehealth movement in its mission to improve quality of life for pets, pet parents, and veterinary professionals globally. The platform differentiates as the only global marketplace empowering veterinarians to provide virtual care, as well as supporting more than 20 species of animals – not just cats and dogs.

Vetster connects pet parents to thousands of licensed veterinarians through video chat appointments 24/7. With a 97% five star consumer rating, Vetster allows pet parents the freedom to choose a practitioner based on their specialty, location, or availability and see their flat-rate fee upfront, enabling them to make informed decisions that align with their modern lifestyle and budget.

At the intersection of two mega trends – 1. Pet Adoption and 2. Telemedicine, Vetster’s triple-digit growth has skyrocketed since launching in November 2020. In April of 2022, the company secured $30 million USD in an oversubscribed Series B round, announcing an exclusive partnership with e-commerce provider PetMeds – the first of its kind to enable pet telemedicine on a mass scale. The partnership allows Vetster to integrate medications and over-the-counter products directly into the appointment experience, offering convenient and efficient delivery of prescriptions and over-the-counter pet medications.

By harnessing the power of telehealth, Vetster allows qualified veterinarians to treat conditions including: skin issues, gastrointestinal, vomiting and diarrhea, behavioral concerns, minor cuts and wounds, dietary concerns, puppy and kitten wellness and training, as well as general pet health and wellness questions.

The mission of the annual Pet Innovation Awards Program is to honor innovation and recognize the excellence, hard work and success in a range of Pet Care industry categories, including Apparel, Grooming & Cleaning, Food & Treats, Health, Housing, Toys, Training, Retailers & Services and more. The 2022 Pet Innovation Awards attracted more than 2,000 nominations from around the world.

“It’s a crisis that so many animals don’t always have access to the care they need. This impacts both urban and rural environments. Veterinarians may not be readily available – especially if you need a specialist. Telehealth can change the conversation,” said Travis Grant, Managing Director, Independent Innovation Awards. “Vetster is leading the global veterinary telehealth movement and revolutionizing the global pet care industry by bringing telehealth mainstream. Congratulations on being our choice for ‘Pet App of the Year.’”

Currently available in the USA, Canada and the UK and with more than 4,000 licensed vets in every state and province, Vetster plans to expand into the rest of the world in 2023.

####

About The Pet Innovation Awards

Part of Independent Innovation Awards organization, a global market intelligence and recognition program within the most competitive consumer categories, The Pet Innovation Awards honors the most outstanding and innovative companies, services, and products within the rapidly expanding pet care industry. The Pet Innovation Awards provides public recognition for achievements of pet care industry companies and products including Apparel, Grooming & Cleaning, Food & Treats, Health, Retailers & Services and more. For more information visit: https://petinnovationawards.com.

About Vetster

Vetster is the leading veterinary telehealth platform connecting pet owners with top-rated veterinary professionals. Pet owners use Vetster to speak to veterinary professionals online through video, text, or audio chat. Vetster’s award-winning marketplace and mobile app empower pet owners to speak with a veterinarian from the comfort of home or while traveling, scheduling appointments any time — 24/7. Create a free account today at vetster.com.

Share article on social media or email:

Use of Continuous Circadian Intracerebroventricular Administration of Anaerobic-Dopamine Reduces Levodopa-Related Complications


International Congress of Parkinson’s Disease and Movement Disorders ®

International Congress of Parkinson’s Disease and Movement Disorders ®

“It is a significant result in four patients, which deserves attention. An alternative to oral treatment that reduces dyskinesias and ‘off’ periods between 80% to almost disappearance has a large effect.”

Use of continuous intracerebroventricular (i.c.v.) administration of anaerobic dopamine (A-dopamine) showed a significant reduction in dyskinesias in a study released today at International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

Long-term use of levodopa/carbidopa often leads to development of unwanted motor symptoms in patients with Parkinson’s disease. These unwanted motor symptoms are termed levodopa-induced dyskinesias. Many alternate therapy options have been investigated as ways to stave off dyskinesia.

Moreau et al. and colleagues developed early clinical trials to assess the practicality of using i.c.v administration of dopamine. These early investigations failed due to the accelerated dopamine oxidation and tachyphylacxia. Their most recent investigation sought to investigate the safety and efficacy of i.c.v. of A-dopamine treatment versus the standard oral treatment in treating levodopa-related complications (LDRC). A total of four patients were assessed over two 1-month periods in an open-label randomized trial. Use of i.c.v. A-dopamine showed a greater reduction in dyskinesias compared to the standard oral treatment.

Stella Papa, Professor in the Department of Neurology at the Emory School of Medicine, responded to this study, “It is a significant result in four patients, which deserves attention. An alternative to oral treatment that reduces dyskinesias and ‘off’ periods between 80% to almost disappearance has a large effect. Results also show dose-dependent effect size, adding support to the data.”

View the abstract full text:

http://www.mdsabstracts.org

Reference #: 1030

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

SpyGlass Pharma to Unveil Innovative Drug Delivery Platform for Chronic Eye Conditions at Eyecelerator Prior to the American Academy of Ophthalmology Meeting


SpyGlass Pharma Logo

SpyGlass Pharma, Inc.

SpyGlass Pharma, a privately-held ophthalmic therapeutics company, today announced it will be unveiling a breakthrough drug delivery platform to treat chronic eye conditions at the Eyecelerator innovation meeting, being held prior to the American Academy of Ophthalmology (AAO) 2022 conference, September 29, in Chicago.

“After three years of groundbreaking work, we are delighted to unveil our breakthrough drug delivery platform that will enable all cataract surgeons to provide multi-year therapy to treat a chronic ophthalmic condition while patients undergo a common eye procedure,” said Patrick Mooney, CEO of SpyGlass. “Notably, we have already begun developing a pipeline of potential drug products using this novel platform, and we are excited to share some initial program data with the ophthalmic community. The SpyGlass platform presents a new paradigm for the treatment of various chronic eye conditions, and its successful development could lead to better outcomes for both patients and physicians.”

Details on SpyGlass’ Eyecelerator 2022 Presentation:

Oral Presentation Title: “Drug Delivery – That Lasts”

Presentation Session: Pharma and Implants session

Presentation Time: 2:00 PM CDT/ 3:00 PM EDT

Presenting Speaker: Patrick Mooney, CEO

About SpyGlass Pharma

SpyGlass Pharma was co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman in 2019. The company is focused on the development of novel treatments for chronic ophthalmic diseases. The company’s technology was originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and is funded by New Enterprise Associates and Vensana Capital. For more information please visit: http://spyglasspharma.com

Share article on social media or email:

RevSpring Opens New Corporate Headquarters in Nashville


“Our new office will support a modern, flexible working environment for our local and remote teams, employees and customers, to gather, collaborate and innovate,” said MacKenzie, RevSpring CEO.

RevSpring, the leading provider of healthcare patient engagement and payment solutions, announced today the grand opening of its new corporate headquarters in Nashville. The move will establish RevSpring’s primary home among many of the industry’s largest healthcare networks, providers and revenue cycle partners.

Located at 1131 4th Avenue South, RevSpring’s new corporate headquarters will occupy 9,304 square feet of space on the third floor of Nashville Warehouse Co., with space for more than 80 employees. RevSpring has nearly 800 employees nationwide in cities and remote offices across the U.S., including Phoenix, Arizona; Detroit, Michigan; Minneapolis, Minnesota; Trenton, New Jersey; Columbus, Ohio; and Philadelphia, Pennsylvania.

“This is an exciting milestone for RevSpring,” said RevSpring CEO Scott MacKenzie. “In addition to being a beautiful new location in a vibrant city known for excellence in healthcare, the office is designed to embrace the new way people work in the wake of the pandemic. Our new office will support a modern, flexible working environment for our local and remote teams, employees and customers, to gather, collaborate and innovate.”

The new headquarters is being commemorated today with a ribbon-cutting ceremony to celebrate the new office space.

The move builds upon a year of ongoing momentum for the company, driving double-digit year-over-year revenue growth for the business:

  • Continued sales momentum with record bookings over the past year and a half, including more than 300 new client logos added for new direct customers and channel partners
  • Better than 30% revenue growth in each of the past two years in the payments business, with more than 35 million payment transactions made and nearly $8 billion collected in the past 12 months
  • Merchant payments volume processed at over $1 billion annual run rate and at a 70% growth rate year-over-year
  • Double-digit growth in RevSpring’s analytics business, which adds intelligence to patient engagement and payments, everywhere
  • Triple-digit growth in digital delivery as clients embrace an intelligent, omnichannel engagement strategy for billing and payment
  • Continued expansion of preservice applications into RevSpring’s revenue cycle client base, marked by double-digit growth in our preservice business
  • Healthy post-COVID growth in RevSpring’s billing business (print and mail)

And ongoing innovation, with more than 12 new products announced in 12 months, including:

  • Deviceless Payments™
  • Safe Mode™ for call center PCI compliance
  • Analytics-driven patient journey visualization and optimization through OmniBrain™
  • OCR with Arrived™ patient intake forms
  • Talksoft® patient self-scheduling
  • New integrations to PersonaPay™ with Epic, Cerner and leading digital wallet and financing companies
  • IDSecure™ for secure consumer data tokenization throughout production
  • Composer™ content management and self-service solutions

RevSpring is focused on solutions that increase customer revenues, increase patient/consumer self-service and engagement, and reduce the cost to engage with patients and consumers. RevSpring solutions are focused on the need to increase revenues, reduce discretionary services, adapt to remote staffing models, staff reduction and retention challenges, and cost pressures. In addition to driving unmatched consistency in the patient experience—spanning preservice to payment—RevSpring uses intelligence and personalization to support critical healthcare business goals, including increased collections, patient experience, patient loyalty and cost efficiency.

“As the healthcare industry continues to change and evolve, the patient expectation and experience is changing. We want our workplace to reflect these changing ways to engage. Engagement in healthcare requires a masterful balance of innovation, empathy and perseverance—and RevSpring is revolutionizing healthcare solutions, spearheading innovations in patient experience and payments, and driving improvement,” added MacKenzie.

About RevSpring

RevSpring leads the market in patient engagement and payment solutions that inspire patients to participate in and pay for their healthcare. The company has built the industry’s most comprehensive and impactful suite of patient engagement, OmniChannel communications and payment solutions backed by behavior analysis, propensity-to-pay scoring, contextual messaging, and user experience best practices. Using proprietary data analytics to tailor the engagement from preservice to post-service, RevSpring improves the patient experience and outcomes for providers and their patients. To learn more, visit revspringinc.com/healthcare.

Share article on social media or email:

QSM Diagnostics Builds Momentum Heading into Fourth Quarter


“It feels like we are really starting to hit our stride,” says Ed Goluch, PhD, Founder and CEO of QSM Diagnostics.

QSM Diagnostics, a diagnostic device and testing company that helps veterinarians improve their diagnoses and treatment plans, to provide better animal care and pet owner satisfaction, has been gaining steady traction in the pet tech space with the launch of several new mail-in test products and customer facing features.

New Product Innovation

Adding depth to their current mail-in testing product lineup, QSM Diagnostics recently added a Cat Urinalysis with Culture and Sensitivity Kit and Dog/Cat Fecal Kit to their FetchDx portfolio. These kits help veterinarians with home re-checks, are ideal for telehealth use, and are great for monitoring chronic conditions.

The Cat Urinalysis with Reflex Culture and Sensitivity Kit


  • Ideal for UTI rechecks after treatment and assisting with compliance of the veterinarian prescribed treatment plan
  • Great for telehealth appointments where urinary tract issues are identified
  • The reflex culture & sensitivity test distinguishes pathogens from contamination
  • Significantly more accurate and sensitive than dip stick testing alone
  • More accurate test results are obtained with less stress for cats by collecting the sample at home


The New Fecal Kit FetchDx Fecal Sample Kit Allows for:

  • Ova and Parasite testing via centrifugation
  • Giardia antigen testing performed with ELISA
  • Results can be obtained prior to a pet’s annual wellness exam to help minimize the number of trips the pet owner needs to make to the clinic
  • Results are available within 24 hours the sample arriving at the laboratory
  • Results stored and always available for pet owners in our free webapp
  • Results shared via email with clinics (custom veterinarian webapp coming soon)

“It feels like we are really starting to hit our stride,” says Ed Goluch, PhD, Founder and CEO of QSM Diagnostics. “The team has been working really hard to provide the kinds of tools and services veterinarians and pet owners need to get the most from our products.”

New Customer Features FetchDx Telehealth Membership Benefits

QSM Diagnostics now offers FREE unlimited 24/7 access to licensed veterinarians through texting or video calling to assist pet owners with sample collection. No appointment is required and the average wait time to speak with a veterinarian is less than 2 minutes. Pet owners can also discuss their pet’s symptoms with veterinarians and determine if home testing is appropriate for their pets.

New FetchDx Pet Owner Portal Features Ensure Smoother User Experience

A first for the animal health industry, the new FetchDx portal stores all test results as discreet data to allow researchers to track companion animal health trends across the United States. Pet owners can review test results in a discreet format with educational links and wellness recommendations. The test results are stored in the cloud, so pet owners can access them at any time, share records with veterinarians quickly and easily, and track their pets. The portal also allows linking with other animal activity and wellness trackers to provide a more complete picture of a pet’s health.

ABOUT QSM DIAGNOSTICS

Boston, Massachusetts-based QSM Diagnostics Inc. is fundamentally changing how infections are diagnosed and treated. The company’s patented technology allows veterinarians to diagnose and monitor infections in companion animals rapidly and accurately. The ease-of-use of the instrument and mail-in platforms reduces workload for healthcare providers and improves the standard of care.

Share article on social media or email:

ABQAURP Announces the 2023 CHCQM Diplomate Achievement Award


CHCQM Diplomate Achievement Award

The Award will identify leaders whose outstanding initiatives have led to measurable change and improvement in: patient safety outcomes, provider and/or patient engagement, and overall quality improvements.

ABQAURP Diplomates have voluntarily achieved certification in Health Care Quality and Management (CHCQM); demonstrating commitment to patient safety, health care quality, and effective care. ABQAURP’s long-standing membership attests to the value certification brings throughout your health care career.

To recognize the achievements of Diplomates with outstanding initiatives in health care quality and patient safety that have led to measurable improvements in the advancement of the field, ABQAURP presents the CHCQM Diplomate Achievement Award bi-annually in conjunction with the Annual Health Care Quality & Patient Safety Conference (HCQ&PS).

The Award is presented to recognize the Diplomate that best embodies the values of the medical profession through leadership, service, excellence, and integrity; demonstrating commitment to advancing ABQAURP’s mission to improve the quality of health care!

The Award will identify leaders whose outstanding initiatives have led to measurable change and improvement in: patient safety outcomes, provider and/or patient engagement, and overall quality improvements.

The deadline for submissions is March 1, 2023. The Award will be presented at the 46th Annual Health Care Quality & Patient Safety Conference on October 19-20, 2023, in Clearwater Beach, FL.

Award recipient will be invited to present their innovation to attendees at the conference and will receive complimentary conference registration including a two-night hotel stay.

More information and applications are found at: http://www.abqaurp.org/award.

About ABQAURP

Celebrating 45 years of excellence in Health Care Quality Management and Patient Safety, ABQAURP is a premier professional association providing Health Care Quality and Management (HCQM) certification, ACCME-accredited continuing medical education, and membership to health care professionals worldwide. For more information about ABQAURP programs: call (800) 998-6030 or visit http://www.abqaurp.org.

Share article on social media or email:

Climbing Shown to Improve Posture in People with Parkinson’s Disease


International Congress of Parkinson’s Disease and Movement Disorders ®

International Congress of Parkinson’s Disease and Movement Disorders ®

Forward flexion of the cervical spine was measured throughout the study in all 46 participants and found to significantly improve in the group that participated in the sport climbing.

Sport climbing in patients with mild to moderate Parkinson’s disease (PD) resulted in improved posture, according to a study released today at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

Patients with PD often have a stooped posture due to forward flexion of the trunk. This 12-week study performed in Vienna, Austria, looked at changes in posture in patients with PD who participated in sport climbing verses those who did unsupervised activity of their choice. Climbing sessions were supervised and totaled 90 minutes per week. Participants in the study did not have prior climbing experience. Forward flexion of the cervical spine was measured throughout the study in all 46 participants and found to significantly improve in the group that participated in the sport climbing. (Langer et al.,2022)

Prof. Michele Tinazzi, Professor of Neurology at University of Verona, commented, “The authors demonstrated that sport climbing significantly decreases forward flexion of the cervical spine in PD patients and concluded that this study provides strong evidence that sport climbing improves stooped posture in mild to moderate Parkinson disease. Stooped posture is often seen in PD patients and is characterized by mild anterior trunk flexion of the trunk and of the neck with mild hip and knee flexion. Very recently, an MDS task-force consensus on nosology and cut-off for axial postural abnormalities (Tinazzi et al. Mov Dis Clin Pract 2022) found a full agreement for the following terms and cut-offs: camptocormia, with thoracic fulcrum (>45°) or lumbar fulcrum (>30°), antecollis (>45°); anterior trunk flexion,” with thoracic (≥25°to ≤45°) or lumbar fulcrum (>15°to ≤30°), and “anterior neck flexion” (>35° to ≤45°) were chosen for milder postural abnormalities.”

Prof. Tinazzi continues, “In the present study, the authors did not define the anterior trunk or neck flexion using this validated approach but using the distance (in cm) of the seventh cervical vertebra (C7) sagittal vertical axis (C7SVA) from the wall was defined when standing upright against a wall. This approach is not adequate to really detect the above anteroflexion postural abnormalities. Notwithstanding this limitation, the present study and the previous one of the same group suggests that sport climbing improves motor symptoms and possibly also the stooped posture in PD. Future ad hoc studies in PD patients with different anteroflexion postural abnormalities and different degrees using the validated software-based measurements are needed to confirm these important preliminary results.”

View full abstract text:

http://www.mdsabstracts.org

Reference # 739

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

REFERENCES

Langer, A. et al. (2022, September 15). Climb up! Head up! Climbing Improves Posture in Parkinson’s Disease. A randomised controlled trial [abstract]. In: Movement Disorders journal online supplement; International Congress of Parkinson’s Disease and Movement Disorders®. Retrieved from https://www.mdsabstracts.org/, Reference #739.

Share article on social media or email:

Regardless of Type, Exercise Improves Quality of Life and Motor Function in People with Parkinson’s Disease


International Congress of Parkinson’s Disease and Movement Disorders ®

International Congress of Parkinson’s Disease and Movement Disorders ®

“The current systematic review provides much more positive news about the effects of exercise as a therapeutic strategy.”

In a Cochrane systematic review and network meta-analysis of studies of physical interventions (exercise), it was shown that regardless of the specific type of exercise that is studied, there is an overall improvement in measures of quality of life and motor function for people with Parkinson’s disease (PD), according to the analysis released today at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

This study represents a significant increase in the number of studies focused on the role of exercise in PD. It was noted that 156 studies were evaluated in this study, a substantial increase from a decade prior. The analysis concluded that there was a clear consensus of benefits in motor function and quality of life across studies. Reported safety measures were also evaluated and concluded that the studied exercise was relatively safe with minimal adverse events reported.

Alice Nieuwboer, professor in the Department of Rehabilitation Sciences at KU Leuven, commented, “The current systematic review provides much more positive news about the effects of exercise as a therapeutic strategy. Effect sizes of exercise, which were only deemed small in 2012 and only applied to motor function, show today that movement therapy generates at least moderate effect sizes on motor function and impacts quality of life. What is more, the risks of exercise were found to be low. Therefore, despite detecting considerable risk of bias in the included study material, this review brings the overall positive message that engaging in movement therapy is safe and worth the effort. The next challenge is to address how people with PD across the world can access and take up exercise in the most cost-effective way, particularly in underserved areas.”

Prof. Nieuwboer continues, “One conclusion from this review deserves some more critical thought. Ernst et al found beneficial effects for most types of exercise and subsequently concluded that ‘any movement counts,’ irrespective of the type of activity. This greatly overestimates the physiological benefits of exercise and underestimates the complexity of delivering it in the context of a heterogenous disease such as PD. More and more, scientific evidence underscores that exercise effects depend on patients’ clinical profiles and on the dose of this activity, which typically needs to be high and progressive.”

View full text:

http://www.mdsabstracts.org

Reference #: 234

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email: